SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009142
Filing Date
2023-05-10
Accepted
2023-05-10 16:34:25
Documents
60
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20230331x10q.htm   iXBRL 10-Q 839911
2 EX-31.1 anvs-20230331xex31d1.htm EX-31.1 13510
3 EX-31.2 anvs-20230331xex31d2.htm EX-31.2 13547
4 EX-32.1 anvs-20230331xex32d1.htm EX-32.1 5705
5 EX-32.2 anvs-20230331xex32d2.htm EX-32.2 5694
  Complete submission text file 0001558370-23-009142.txt   4436904

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20230331.xsd EX-101.SCH 30230
7 EX-101.CAL anvs-20230331_cal.xml EX-101.CAL 21247
8 EX-101.DEF anvs-20230331_def.xml EX-101.DEF 121532
9 EX-101.LAB anvs-20230331_lab.xml EX-101.LAB 254376
10 EX-101.PRE anvs-20230331_pre.xml EX-101.PRE 222087
54 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20230331x10q_htm.xml XML 777164
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 23907095
SIC: 2834 Pharmaceutical Preparations